Ketamine: Translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders

Molecular Psychiatry

Volumn 22, Issue 3, 2017, Pages 324-327

  Zarate, C A ^a   Machado Vieira, R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ADIPONECTIN; AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; COLURACETAM; ELONGATION FACTOR 2; GLUTAMATE RECEPTOR 1; GLYCOGEN SYNTHASE KINASE 3; KETAMINE; LANICEMINE; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RAPASTINEL; RESISTIN; AMINO ACID RECEPTOR BLOCKING AGENT;

ANTIDEPRESSANT ACTIVITY; CALCIUM TRANSPORT; CYSTITIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; HIPPOCAMPUS; HUMAN; INTRACELLULAR SIGNALING; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PILOT STUDY; POSTTRAUMATIC STRESS DISORDER; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PYRAMIDAL NERVE CELL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS; TREATMENT RESISTANT DEPRESSION; UPREGULATION; ANIMAL; CHEMISTRY; MOOD DISORDER;

ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; MOOD DISORDERS;

EID: 85008618964     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.249     Document Type: Review

References (39)

1. Iadarola ND, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB et al. Ther Adv Chronic Dis 2015; 6: 97-114.
2. Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al. Arch Gen Psychiatry 2006; 63: 856-864.
3. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB et al. Am J Psychiatry 2015; 172: 950-966.
4. Diazgranados N, Ibrahim L, Brutsche N, Newberg A, Kronstein P, Khalife S et al. Arch Gen Psychiatry 2010; 67: 793-802.
5. Lally N, Nugent AC, Luckenbaugh D, Niciu MJ, Roiser JP, Zarate CA. J Psycho-pharmacol 2015; 29: 596-607.
6. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Transl Psychiatry 2014; 4: e469.
7. Saligan LN, Luckenbaugh D, Slonena EE, Machado-Vieira R, Zarate CAJ. J Affect Disord 2016; 194: 115-119.
8. Abdallah CG, Sanacora G, Duman RS, Krystal JH. Annu Rev Med 2015; 66: 509-523.
9. Niciu MJ, Mathews DC, Nugent AC, Ionescu DF, Furey ML, Richards EM et al. Depress Anxiety 2014; 31: 297-307.
10. Gerhard DM, Wohleb ES, Duman RS. Drug Discov Today 2016; 21: 454-464.
11. Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC et al. Biol Psychiatry 2016 (e-pub ahead of print 12 May).
12. Sanacora G, Heimer H, Hartman D, Mathew SJ, Frye M, Nemeroff CB et al. Neuropsychopharmacology 2016 (e-pub ahead of print 12 October).
13. Skolnick P, Popik P, Trullas R. Trends Pharmacol Sci 2009; 30: 563-569.
14. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al. Biol Psychiatry 2000; 47: 351-354.
15. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CAJ. Pharmacol Ther 2009; 123: 143-150.
16. Machado-Vieira R, Manji HK, Zarate CA. Neuroscientist 2009; 15: 525-539.
17. Malinow R, Malenka RC. Annu Rev Neurosci 2002; 25: 103-126.
18. Maeng S, Zarate CA, Du J, Schloesser RJ, McCammon J, Chen G et al. Biol Psychiatry 2008; 63: 349-352.
19. Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M et al. Science 2010; 329: 959-964.
20. Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA. Curr Top Med Chem 2013; 13: 26-54.
21. Dutta A, McKie S, Deakin JF. Psychiatry Res 2015; 225: 1-13.
22. Nations KR, Dogterom P, Bursi R, Schipper J, Greenwald S, Zraket D et al. J Psychopharmacol 2012; 26: 1525-1539.
23. Machado-Vieira R, Henter ID, Zarate CA. Prog Neurobiol 2015 (e-pub ahead of print 23 December); pii: S0301-0082(15)30038-1; doi: 10.1016/j.pneurobio.2015.12.001.
24. Martinowich K, Jimenez DV, Zarate CA, Manji HK. Mol Psychiatry 2013; 18: 856-863.
25. Yang B, Zhang JC, Han M, Yao W, Yang C, Ren Q et al. Psychopharmacol (Berl) 2016; 233: 3647-3657.
26. Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK et al. Neuropsychopharmacology 2013; 38: 729-742.
27. Jaso BA, Niciu MJ, Iadarola ND, Lally N, Richards EM, Park M et al. Curr Neuro-pharmacol 2016 (e-pub ahead of print 21 March).
28. Chen K-T, Tsai M-H, Wu C-H, Jou M-J, Wei I-H, Huang C-C. Front Behav Neurosci 2015; 9: 162.
29. Popp S, Behl B, Joshi JJ, Lanz TA, Spedding M, Schenker E et al. F1000Research 2016; 5: 634.
30. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF et al. Nature 2011; 475: 91-95.
31. Nosyreva E, Szabla K, Autry AE, Ryazanov AG, Monteggia LM, Kavalali ET. J Neu-rosci 2013; 33: 6990-7002.
32. Kavalali ET, Monteggia LM. Am J Psychiatry 2012; 169: 1150-1156.
33. Beurel E, Song L, Jope R. Mol Psychiatry 2011; 16: 1068-1070.
34. Beurel E, Grieco SF, Amadei C, Downey K, Jope RS. Bipolar Disord 2016; 18: 473-480.
35. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI et al. Nature 2016; 533: 481-486.
36. Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L et al. Eur J Pharmacol 2013; 698: 228-234.
37. Du J, Machado-Vieira R, Maeng S, Martinowitch K, Manji HK, Zarate CA Jr. Drug Discov Today Ther Strateg 2006; 3: 519-526.
38. Maeng S, Zarate CA. Curr Psychiatry Rep 2007; 9: 467-474.
39. Machado-Vieira R, Gold PW, Luckenbaugh D, Ballard ED, Richards EM, Henter ID et al. Mol Psychiatry 2016 (this issue).